Exact Expects FDA Approval For Cologuard Plus In Second Half Of 2024, Featuring 30% Lower False-Positive Rate Compared To Original Cologuard, Improving Cancer Sensitivity And Specificity
Exact Expects FDA Approval For Cologuard Plus In Second Half Of 2024, Featuring 30% Lower False-Positive Rate Compared To Original Cologuard, Improving Cancer Sensitivity And Specificity
Exact希望Cologuard Plus在2024年下半年獲得FDA批准，相比原始的Cologuard，其假陽性率降低了30%，提高了對癌症的敏感性和特異性。
Exact Expects FDA Approval For Cologuard Plus In Second Half Of 2024, Featuring 30% Lower False-Positive Rate Compared To Original Cologuard, Improving Cancer Sensitivity And Specificity
Exact預計，Cologuard Plus將在2024年下半年獲得美國食品藥品管理局的批准，其假陽性率比原來的Cologuard低30％，從而提高癌症敏感性和特異性
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。